Alterity Therapeutics wins FDA alignment for pivotal Phase 3 neurodegenerative trial
Alterity Therapeutics (NASDAQ:ATHE) has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), securing critical regulatory alignment on the design of its upcoming pivotal Phase 3 clinical program for lead candidate ATH434.
The therapeutic asset is being developed to treat Multiple System Atrophy (MSA), a rare, rapidly progressive, and highly debilitating neurodegenerative disorder that currently has no approved disease-modifying therapies available to patients.
During the regulatory review, the FDA concurred with the core parameters of Alterity's proposed registrational framework, endorsing the targeted study population, a 50 mg twice-daily dosing regimen, and the planned treatment duration.
Crucially, the agency agreed that the 11-item Unified Multiple System Atrophy Rating Scale (UMSARS) Part I will serve as the trial's primary endpoint to evaluate clinical efficacy.
The FDA also accepted the company's proposed statistical analysis methodologies and key secondary efficacy measures, establishing a standardized structure intended to support a future New Drug Application (NDA) for marketing approval in the United States.
The agency's alignment is underpinned by encouraging data generated during Alterity’s Phase 2 clinical evaluation.
In that study, the 50 mg twice-daily dose of ATH434 achieved clinically and statistically significant efficacy metrics, demonstrating a 48% slowing of symptomatic disease progression compared to the placebo cohort.
To support its late-stage development vector, ATH434 already maintains Fast Track and Orphan Drug designations from the FDA for MSA, which may grant the firm access to expedited regulatory reviews and rolling submissions upon successful trial completion.
With the primary clinical, dosing, and regulatory milestones now finalized, Alterity is moving forward with operational preparations to launch its pivotal Phase 3 trial.
The company confirmed that study initialization activities remain on schedule to commence by the end of 2026.
